Gyala Therapeutics
Gyala Therapeutics is focused on developing new CAR-T therapies for treating hematological malignancies. CAR-T (chimeric antigen receptor T cells) is a type of gene therapy in which T lymphocytes -a type of white blood cells that play a key role in immune responses- are extracted from the patient and modified to attack tumour cells. T lymphocytes are obtained through apheresis (a technique that allows separation of blood components) and genetically reprogrammed with a receptor that binds to a tumor factor. When these cells are transduced back to the patient, they are to specifically recognize tumour cells and attack them. Several types of CAR-T cells have demonstrated efficacy in the treatment of leukemias and B cell lymphomas.
Tech Stack (14 technologies)
Frequently Asked Questions
What technologies does Gyala Therapeutics use?+
Gyala Therapeutics uses 14 technologies including Elementor, WordPress, Cloudflare Turnstile.
What industry is Gyala Therapeutics in?+
Gyala Therapeutics operates in the Biotechnology industry.
Where is Gyala Therapeutics based?+
Gyala Therapeutics is headquartered in Spain.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026